Company
Heron Theraps INC
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
4
3 still marketed
Novel approvals
1
Approvals since 2021
4
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Zynrelef Kit new use Jan 23, 2024
- Aponvie approved NovelSep 16, 2022
- Zynrelef Kit new use Dec 8, 2021
- Zynrelef Kit approved Breakthrough therapyPriority reviewMay 12, 2021
- Cinvanti new use Oct 21, 2019
- Cinvanti new use Feb 26, 2019
- Cinvanti approved Nov 9, 2017
- Sustol approved Aug 9, 2016
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (3)
Newest FDA action first.
- Zynrelef Kit Bupivacaine, Meloxicam · 2021
- Cinvanti Aprepitant · 2017
- Aponvie Aprepitant · 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.